PR98905

EAST RUTHERFORD, N.J., Nov. 21, 2022 /PRNewswire=KYODO JBN/--

Cambrex, a leading global contract development and manufacturing organization

(CDMO) providing drug substance, drug product, and analytical services across

the entire drug lifecycle, today announced that it has entered into a

definitive agreement to acquire Snapdragon Chemistry, a leading US-based

provider of chemical process development services to a broad range of emerging

and established biopharma customers.

Snapdragon specializes in active pharmaceutical ingredient (API) batch and

continuous flow process development, utilizing state-of-the-art automation

technology and proprietary equipment to solve complex process and analytical

development challenges. The team of scientists and engineers apply deep process

understanding afforded by data-rich experimentation to design and rapidly

execute efficient GMP and non-GMP manufacturing processes. With R&D and

manufacturing headquartered in Waltham, Massachusetts, Snapdragon's 74

employees come with strong ties to the local scientific community, with 31 PhD

scientists on staff.

"The acquisition of Snapdragon will accelerate our growth in the area of

continuous flow process development and manufacturing, complementing our recent

organic investments in our High Point, North Carolina facility," said Tom

Loewald, CEO of Cambrex. "With R&D and manufacturing capabilities in the heart

of Boston's biopharma hub, Snapdragon will continue to focus on solving their

customers' most difficult process development challenges."

"We are excited to be joining Cambrex, a company with over 40 years of drug

substance development and manufacturing expertise," said Matt Bio, CEO of

Snapdragon. "Partnering our best-in-class process development capabilities with

Cambrex's larger scale manufacturing facilities in North America and Europe is

a natural fit, both for our employees and our customers."

Snapdragon recently opened its second facility, a new 51,000-square-foot

facility to manufacture experimental pharmaceutical products for human clinical

trials. The new facility expanded the company's capacity for supplying clinical

intermediates and drug substances.

The transaction is expected to close following the completion of customary

regulatory approvals.  This will be Cambrex's second acquisition within a year

along with Q1 Scientific, consistent with its strategy to expand its portfolio

of specialized solutions for pharmaceutical development and manufacturing.

About Cambrex

Cambrex is a leading global contract development and manufacturing organization

(CDMO) that provides drug substance, drug product, and analytical services

across the entire drug lifecycle. With over 40 years of experience and a

growing team of over 2,300 experts servicing global clients from North America

and Europe, Cambrex is a trusted partner in branded and generic markets for API

and finished dosage form development and manufacturing.

Cambrex offers a range of specialized drug substance technologies and

capabilities, including biocatalysis, continuous flow, controlled substances,

solid-state science, material characterization, and highly potent APIs. In

addition, Cambrex can support conventional dosage forms, including oral solids,

semi-solids, and liquids, and has the expertise to manufacture specialty dosage

forms such as modified-release, fixed-dose combination, pediatric, bi-layer

tablets, stick packs, topicals, controlled substances, sterile, and non-sterile

ointments.

Logo - https://mma.prnewswire.com/media/1198585/Cambrex_Logo.jpg

Source: Cambrex